MCM
BCYC

Moore Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Moore Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Hold
275,000
– – 0.03% 343
2025
Q4 		$1.95M Buy
275,000
+150,000
+120% +$1.11M 0.03% 390
2025
Q3 		$968K Buy
125,000
+50,000
+67% +$377K 0.01% 433
2025
Q2 		$521K Buy
75,000
+25,000
+50% +$199K 0.01% 420
2025
Q1 		$425K Buy
+50,000
New +$589K 0.01% 368

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Moore Capital Management's BCYC Position: Q1 2026 in Review

Moore Capital Management held its Bicycle Therapeutics (BCYC) position steady in Q1 2026 at 275,000 shares worth $1.28M. The position accounts for 0.03% of the portfolio, ranked #343.

Moore Capital Management first reported a position in BCYC in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.95M in Q4 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Moore Capital Management held 275,000 shares of Bicycle Therapeutics worth $1.28M as of Q1 2026.
  • Moore Capital Management left its Bicycle Therapeutics share count unchanged in Q1 2026.
  • Bicycle Therapeutics made up 0.03% of Moore Capital Management's portfolio in Q1 2026, its #343 holding.
  • Moore Capital Management first reported a position in Bicycle Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Moore Capital Management's Bicycle Therapeutics position peaked at $1.95M in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.